Lonza Group AG (LONN) Stock Price, Fundamentals & Analysis

What LONN does

Lonza Group AG (LONN) is a contract development and manufacturing organization that works with pharmaceutical and biotech companies across Europe, the Americas, Asia, and beyond. It operates through three segments: Integrated Biologics (CDMO biologics services, including mammalian and drug product platforms), Advanced Synthesis (antibody-drug conjugates, small molecules, and highly potent active pharmaceutical ingredients), and Specialized Modalities (cell & gene, microbial, bioscience, and mRNA technologies). Incorporated in 1897 and headquartered in Basel, Switzerland, Lonza Group AG employs 20,141 people and is listed on the SIX Swiss Exchange.

Key numbers explained

• 569.2 CHF is the current share price; the -0.14% change shows today's movement.
• The trailing P/E ratio of 36.8 compares the price to the last 12 months of earnings, while the forward P/E ratio of 25.8 uses expected future earnings.
• 15.48 CHF is the trailing 12-month earnings per share, the portion of profit allocated to each share.
• The dividend yield of 0.88% indicates the annual dividend as a percentage of the share price; the ex-dividend date is May 12, 2026, and 32% of earnings are paid out as dividends.
• 39.76B CHF is the market capitalization, the total value of all outstanding shares.
• The beta of 0.84 suggests the stock has historically been less volatile than the overall market.
• The 52-week range of 454.6 – 597.8 CHF shows the lowest and highest prices over the past year, with a 9.7% change over that period.
• 6.87B CHF in trailing 12-month revenue and 11.2% year-over-year growth describe the top-line scale and pace; the operating margin of 23.4% reflects profitability from core operations, while the profit margin of -1.6% shows a net loss relative to revenue.
• The debt-to-equity ratio of 51.1% and price-to-book of 4.89 are additional valuation and leverage indicators.

What to watch

Lonza Group AG operates in the Healthcare sector, specifically Diagnostics & Research, and its performance can be influenced by pharmaceutical and biotech industry cycles, regulatory changes, and demand for contract manufacturing services. Investors often compare it with peers such as Novartis International AG (NOVN), Roche Holding AG (ROP), and Alcon Inc (ALC). Broader factors like interest rates, currency movements, and global healthcare spending trends can also affect stocks of this type.